Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by a disruption in normal hematopoiesis that results in uninhibited myeloblast proliferation. Cutaneous reactions in AML include leukemia cutis, Sweet syndrome, infections, and treatment-related effects. We present 3 cases of FLT3 (OMIM 136351) inhibitor–associated neutrophilic dermatoses (Table).
Varadarajan N, Boni A, Elder DE, Bagg A, Micheletti R, Perl AE, Rosenbach M. FLT3 Inhibitor–Associated Neutrophilic Dermatoses. JAMA Dermatol. 2016;152(4):480-482. doi:10.1001/jamadermatol.2015.6121